Product Description: Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent[1][2].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Bruno François, et al. Safety and tolerability of a single administration of AR-301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by Staphylococcus aureus: first-in-human trial. Intensive Care Med. 2018 Nov;44(11):1787-1796./[2]Philippe Vignon, et al. New Agents in Development for Sepsis: Any Reason for Hope? Drugs. 2020 Nov;80(17):1751-1761.
CAS Number: 1374419-41-6
Molecular Weight: N/A
Compound Purity: 95.00
Research Area: Infection
Solubility: H2O
Target: Antibiotic
English
Deutsch
